David J. Augeri, PhD

augeridavid@gmail.com;(609)-314-1539
https://www.linkedin.com/in/david-augeri-83b0a849/
new website = https://www.djapharmaconsulting.net

Synthetic Organic/Medicinal Chemist, Innovative Problem Solver, Expert Consultant & Expert Witness, Scientific Writing.

Innovative Scientist who is an accomplished medicinal chemist. Experienced in Intellectual Property, in Scientific and Medical Communication, and in Academic Collaborations.

Instrumental Synthetic Organic and Medicinal Chemistry Director with >60 issued U.S. Patents and > 47 peer-reviewed journal publications (cited > 8,400) and a robust consultancy background helping biotechs to forge a reasonable path forward. Recognized Expert Consultant/Chemistry and Expert Witness in diabetes and in oncology drug patent litigation trials able to offer testimony for depositions/cross. Big Pharma Discoveries at Bristol-Myers Squibb and AbbVie: BMS, first: Recognized for discovering DPP4 inhibitor saxagliptin (Onglyza) at BMS for T2DM, FDA 2009 and second: designing lead bcl2 inhibitor using NMR-Structure-Based/Fragment-Based Design in the NMR Research Group to launch the Venclexta program at AbbVie, cancer, FDA 2015. Published the 3 papers that highlighted structure-based design and fragment-based methods fundamental to my approach to generate a lead molecule (6,500 citations for the 3 papers). Serves as Expert Witness, for diabetes and cancer drug-related pharmaceutical litigation trials held in the Federal Courts of the US and Canada. Demonstrated history of synthesizing scientific data and implementing technology strategies. Author of dozens of provisional patent applications. Managed CMC campaigns to 1.0 KG GMP API.
In summary, a Director-Level chemist with innovative problem-solving skills managing multidisciplinary projects after gaining expertise from two big pharma drug discoveries in cancer and diabetes. He co-authored 5 NIH R01s and served as Expert Consultant/Witness on US Federal Court Cases, worked with Morgan-Lewis defending Acerta in Pharmacyclics v. Acerta, a case involving Infringement and enablement-based complaints. He also served on many of the ANDAs covering the newer DPP4 Inhibitors and SGLT2 Inhibitors for T2DM.

Areas of Expertise / Skills

– Industry Leadership Engagement Data-driven Decision Making Efficient and Effective Lead Optimization Opt.PK-PD. Drug Discovery Innovation Drug Design Multidisciplinary Team Leadership Cross-Functional Collaboration Corresponding and/or Primary Author on 11/47 journal publications. Inventor listed on >60 issued US Patents Author of Provisional Patent Applications, Patent and IP Expert Litigation Expert, Expert Witness, Experienced Medical Writer and Pharmaceutical & FDA Compliance Radiochemistry NIH-NSF Funded Investigator Dotmatics Data Warrior and StarDrop.

Career Experience

Bentham Sciences assigned to Journal of Medicinal Chemistry 2025 – Present

Editorial Board Member

DJ Augeri Pharma Consulting, LLC 2012 – Present

Synthetic-Organic & Medicinal Chemist/Drug Design, and Expert Witness, Diabetes and Oncology Drugs

Biotech Preclinical/IND Enabling/CMC/GMP API/FDA

Head operations associated with setup and management of consulting firm offering drug discovery assistance or expert witness/patent litigation assistance to market-leading clientele, including Pharmacyclics v. Acerta (btk, expert consultant), Merck (sitagliptin ANDA, expert witness), BMS (saxagliptin ANDA, expert witness), AstraZeneca (saxagliptin ANDA; Mylan, expert witness), Insmed Pharma (drug design/discovery consulting), Exion Labs (materials science, antiviral polymer), Capital Health Hospitals (wrote Phase 2a Cyberknife study ICH:NCCN protocol for unresectable pancreatic cancer) NJ, Kodikaz Therapeutics (radiolabeled DNA vaccine imaging study), PsychoGenics (collaborated on novel antipsychotic), and Riverside Pharma (early drug discovery). Steer all facets of CMC management while ensuring seamless collaboration between CDMO/CRO laboratories. Perform full review of CDMO-submitted API synthetic routes, IND studies coordination, compound supply management, and entire Regulatory-CMC-Compound Supply chain. Utilize latest tools and technologies, including but not limited to Dotmatics, Data Warrior, and StarDrop Data Management systems.

2016-2025: DJ Augeri Pharma Consulting, LLC Princeton, NJ. DJ Augeri, PhD, Principal

Update on Latest—Academic Collaboration initiated by D Augeri, PhD, Princeton and UNC, Chapel Hill, NC and NIDA, NIH. in early 2023 I initiated an academic collaboration between myself and UNC Chapel Hill Professors Bryan Roth and David Nichols, and Dr. Mary MacDonald, PhD and Dr. Robert Kline, PhD, NIDA, NIH.
Preliminary results show the reduced form is an agonist with 76% of the agonist function of LSD. Professor Gumpper reported that a HTR was observed for the 9,10-dihydro-LSD, confirming its agonist activity at the 5-HT2A receptor.

The following consulting jobs were all 1099 HOURLY paid contracts that were less than 80 hours total over 1-2 years except Exion Labs that was a multiyear contract for ~20+ hours a week. Legal cases varied from 5-10 hrs to 20h/week for 2-3 months and, on occasion, up to 2 years.

–**Designed a novel backup DPP1 inhibitor for Insmed (NJ) in 2022** to follow brensocatib in the clinic) using an unorthodox approach by using the very same PDB file of DPP1-inhibitor complex that Astra Zeneca used to design brensocatib, the lead clinical molecule outlicensed to Insmed (36 h)

–Assisted **Kodikaz Therapeutics 2021-2023** to design a radiolabeled DNA vaccine to conduct an in vivo study to determine the uptake and concentration of cancer vaccine in the target tissue. I helped Anthony Johnson, a very able and hands-on CEO to design a labeled compound to conduct an in vivo study to determine the uptake and concentration of cancer vaccine in the target tissue, the liver. The desferoxamine DFO linker was chosen to link to a DNA oligonucleotide vaccine (by the –NH2 of the terminal guanine) and to chelate to Zr-89 (the 3 hydroxamic acid moieties known to dump lone electron pairs into Zr89 D-orbitals). The DFO was linked through a thioisocyanate to the guanine –NH2 of the terminal DNA base of the oligo DNA vaccine. Kodikaz was pleased to observe it to localize in the liver, the desired target tissue for unresectable hepatic carcinoma in this in vivo imaging study. 3-4 weeks where each week's effort separated by a few month until complete.

–**Consulted Exion Laboratories (Iowa, US, 2021-2023)** to help to develop proprietary Polyethylenimine (LPEI)-polymer based products 10-20 h/week for 18 months

–**Authored a Phase 2a clinical trial ICH-guided protocol** for an oncology group at Capital Health Hospitals in NJ (wrote the ICH-guided protocol for Phase 2a "cyberknife" trial used as an advanced motion-sensitive radiation therapy in nonresectable pancreatic adenocarcinoma). Also wrote journal manuscripts for the oncologists. On and off for 2 years. 10h/week.

–**Legal – Expert Consultant / Expert Witness** on 18 cases since 2014. I have been an expert synthetic organic chemistry consultant or expert witness on 18 cases that involved Pharmacyclics v. Acerta over btk inhibitors ibrutinib and acalabrutinib, the ANDAs for DPP4 Inhibitors (Januvia, Onglyza and others) and the ANDAs for all of the SGLT2 Inhibitors. Cases vary widely.

Rapafusyn Pharmaceuticals Med Chem and CMC PROJECT Full time-Consult. 03-2022 to 11-2022. Redesigned library to infuse heterocyclic congeners of Alpha Aas (such as subst. pyrimidine for Phenyl of Phe, N-Me Pyrazole for Phenylglycine, substituted a morpholine ring for pyrrolidine in a D-Pro, all 3 reduced macrocycle CLogP from 8.87 to 4.92). Managed full spectrum of CMC while steering the synthesis of 1.0 kilo API under both GLP and GMP guidelines.

- Oversaw CMC facets of Phase 1/GLP + GMP-API for the rapadocin drug, facilitating FIM study post-IND submission.
- Organized CDMOs, scrutinized chemistry capabilities, timelines, cost-efficiency, drug substance production from API, IV formulations, delivery dates, and analytical chemistry.

Rutgers University, Piscataway, NJ **2013 – 2020**

Professor of Synthetic Organic Chemistry—Taught graduate synthesis course(s). - Asymmetric Organic Chemistry, pericyclic reaction mechanisms, polycyclic ring construction strategies, Terpene Indole Alkaloids illustrate Nature's way to diversify the shape and physical properties of isomeric compounds by varied placement of the bridgehead nitrogen. Particular attention paid to strychnos (the MacMillan and the Overman synthesis of strychnine), aspidosperma (aspidospermidine, tabersonine) iboga (corynanthe) and the Woodward landmark synthesis of the yohimbine alkaloid (reserpine). Conformational analysis carefully covered for select syntheses.

- Fostered relationships with industry professionals and research organizations to form collaborations.
- Collaborated / co-authored w/PIs; NIH R01–5 funded R01s (2.8-3.1 $M), 1 NIH R21 and 1 DoD grant (2.8M$)

Lexicon Pharmaceuticals, Princeton, NJ **2003 – 2012**
Director of Immunology Medicinal Chemistry

Led teams of 16 to 18 scientists (PhDs, MS) that achieved 3 INDs for RA (rheumatoid arthritis) and MS (multiple sclerosis). Mentored group in optimization of potency and physical properties with a single structural change– Analogs showed higher binding affinity and improved features of permeability/EC_{50} and PK. Mentoring many manuscripts and external presentations.

Bristol-Myers Squibb Pharmaceuticals **1999–2003**

Research Investigator I/II - Metabolic Diseases Research

Invented ONGLYZA (saxagliptin), FDA Approval 2009 as DPP4 TD2 | Augeri* et al., J Med Chem 2005, 48, 5025-5037.

AbbVie Pharmaceuticals **1995 – 1999**

Research Investigator, NMR Group, Oncology-Fragment-Based Drug Discovery

Invented Acylsulfonamide lead for AbbVie Venclexta—NMR Structure-based design of Lead Molecule Bcl-2/Bcl-XL inhibitor (acylsulfonamide) that launched 15-person effort that discovered VENCLEXTA (venetoclax, Bcl-2 inhibitor, CML and B-cell cancer).

- Published 3 papers on the structure/fragment-based design of the acylsulfonamide, serving as BOTH an isosteric replacement for the Site 1 carboxylic acid AND as a linker that delivers the Site 2 ligand with precise trajectory into Site 2 giving the 36 nM lead acylsulfonamide.
- Venclexta approved by FDA 2015.

Communication Skills – quality, spoken and written. Pls see, J Med Chem, 2005, 48, 5025– dja et al.), 63 issued US Patents, 47 peer-reviewed journal publications, 5 funded NIH R01 proposals.

Education

NIH Postdoctoral Fellow–Princeton University
Dept. of Chemistry, Natural Products, Total Synthesis of the Calicheamicin Oligosaccharide, Advisor, Professor D. Kahne

PhD in Synthetic Organic Chemistry, University of California, Irvine
Dept. of Chemistry, Synthetic Methodology to Prepare Deoxypolypropionate Polyketides Advisor, Professor A.R. Chamberlin

Awards–

–1986 – UConn: Roland Ward Thesis Award for Outstanding Undergraduate Thesis – Awarded by the UConn Department of Chemistry

–1993 – National Institute of Health NRSA Postdoctoral Fellowship, Princeton University Department of Chemistry.

Publications– 2 Key Papers from google scholar

Augeri, David J.*; Robl, Jeffrey A.; Betebenner, David A. ; Magnin, David R.; Khanna, Ashish; Robertson, James G.; Wang, Aiying; Simpkins, Ligaya M.; Taunk, Prakash; Huang, Qi; Han, Song-Ping ; Abboa-Offei, Benoni; Cap, Michael; Xin, Li; Tao, Li ; Tozzo, Effie; Welzel, Gustav E.; Egan, Donald M.; Marcinkeviciene, Jovita; Kirby, Mark S.; Biller, Scott; Parker, Rex A.; Hamann, Lawrence G.* Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes J Med Chem 2005, 48, 5025-5037 (>886 citations).

Oltersdorf, Tilman; Elmore, Steven W.; Shoemaker, Alexander R.; Armstrong, Robert C.; **Augeri, David J.**; Belli, Barbara A.; Bruncko, Milan; Deckwerth, Thomas L.; Dinges, Jurgen; Hajduk, Philip J.; Joseph, Mary K.; Kitada, Shinichi; Korsmeyer, Stanley J.; Kunzer, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435, 677-681 (>4250 citations).

Committees –

–Princeton ACS Fall Organic Chemistry Symposium, Committee Member 2003-2010

–President, Princeton ACS Fall Organic Chemistry Symposium 2010

–Hosted Professor Mohammed Movassaghi, Department of Chemistry, Massachusetts Institute of Technology.

–Hosted Dr. Steven Young, Merck.

–Hosted Professor David Liu, Department of Chemistry, Harvard University

–Hosted Professor Stuart L. Schreiber, Department of Chemistry, Harvard University

Pharmaceutical Achievements, Academic Achievements and Legal Case History

- **UC-Irvine PhD, Synthetic Organic Chemistry** – prepared deoxypolypropionate subunits using a novel hydrazone-mediated diastereoselective alkylation to generate 1,3-skipped *syn*- or 1,3-skipped *anti*-dialkylated chains.
- **Princeton University NIH Postdoctoral Fellowship – Natural Product Synthesis** – prepared calicheamicin oligosaccharide and measured the associated DNA binding affinity.
- **FDA Drug Discovery – AbbVie - Designed the acylsulfonamide lead directly from a ternary NMR structure that launched the Venclexta (bcl-2, cancer)** project. Venclexta contains the acylsulfonamide linker with the necessary geometry and site1/site2 connection points to properly orient it in the Bcl-2 BH3 groove to inhibit bcl-2.
- **FDA Drug Discovery – Bristol-Myers Squibb, discovery of saxagliptin (Onglyza, DPP4 inhibitor, T2DM, FDA2009).**
- 3 INDs in 10 years with this talented group. Nonstop mentoring in drug design (potency and physical properties optimization simultaneously). My Drug Discovery background and training includes considerable knowledge of the ancillary sciences that work in concert with chemistry and biology to discover drugs…biochemistry, immunology, pharmacology (understanding efficacy), medicine, biophysics, pharmacokinetics and pharmacodynamics, and toxicology. I've likely missed a few.
- Academic Funded Grant Proposals: During academics I wrote 7 grant proposals as co-PI that were funded. 5 NIH R01s, 1 DoD grant, 1 NIHR21. These PIs listed were not funded before these grants; they are excellent scientists but needed a different proposal. Each biology"biology" study into a "drug discovery" project and NIH supported this with funding.
- Publications: published 47 peer-reviewed journal articles over my career, 11 as primary and/or corresponding author.
- Patents: I hold 63 issued US Patents and approximately two dozen published non-provisional applications.
- Registered DJ Augeri Pharma Consulting LLC in NJ in 2016, began consulting work in 2012, I conduct both drug discovery consulting, preclinical strategy consulting and pharma patent litigation assistance.
- Pharmaceutical Litigation – Expert Consultant and Expert Witness, US Federal Courts, Canadian Federal Courts.
- Pharmacyclics v. Acerta, 2014 - 2016 (BTK, acalabrutinib/ibrutinib expert consultant)
- Merck (sitagliptin ANDA, expert witness 2018 – 2019)
- BMS (saxagliptin ANDA, expert witness 2018 – 2019)
- Empagliflozin-BI vs. Zydus. Expert regarding Jardiance. 2019
- AstraZeneca 2020-2022 (saxagliptin ANDA; Mylan, expert for Onglyza)
- ANDA Trazodone, 2020 – 2021 Expert Witness
- University of Michigan. Expert regarding Genzyme sphingosine-1-phosphate and ceramide signaling, 2020 – 2021 Expert Witness
- Merck. Canada ANDA. Expert regarding Januvia. 2021 – 2023 Expert Witness
- Linagliptin vs. B.I., Canada. 2021 – 2023 Expert Witness
- Prollenium vs. Allergan. Expert regarding U.S. Patent No. 8,450,475. 2021 – 2022
- Shionogi, Hoffmann-La Roche, and Genentech vs. Norwich Pharma. 2023
- Amgen Canada Inc. & Onyx Therapeutics Inc. v. Dr. Reddy's Laboratories Ltd. 2024, AitkenKlee Expert Witness
- Expert Witness: since 2012 – 18 interesting cases. The US and Canadian Federal Courts require lengthy background reports on either the drug or the general drug class to read in preparation for the case. Provides careful US Patent review containing inventorship of drug/drug class involved and provides input for a potential Markman Hearing, sometimes conducted in the beginning of a trial where infringement is involved. Review/report of any documents submitted for Discovery by opposition. Report relevant questions for Discovery to counsel. Provide Testimony for Depositions and Cross-Examinations

Journal Publications (34 listed here, https://scholar.google.com/citations?user=HlVtCuAAAAAJ&hl=en

John A. Gilleran, Kutub Ashraf, Melvin Delvillar, Tyler Eck, Raheel Fondekar, Edward B. Miller, Ashley Hutchinson, Aiping Dong, Alma Seitova, Mariana Laureano De Souza, **David Augeri**, Levon Halabelian, John Siekierka, David P. Rotella, John Gordon, Wayne E. Childers, Mark C. Grier, Bart L. Staker, Jacques Y. Roberge,* and Purnima Bhanot* "Structure–Activity Relationship of a Pyrrole Based Series of PfPKG Inhibitors as Anti-Malarials" *Journal of Medicinal Chemistry*, **2024**, *67*, February 28, 2024 Articles ASAP.

Li, Xiao-Ping; Harijan, Rajesh; Cao, Bin; Kahn, Jennifer; Pierce, Michael; Tsymbal, Anastasiia; Roberge, Jacques; **Augeri, David**; Tumer, Nilgun. "Synthesis and structural characterization of ricin inhibitors targeting ribosome binding using **fragment-based methods** and **structure-based design**" *Journal of Medicinal Chemistry*, **2021**, *64*, 20, 15334-15348.

Maria Victoria Da Silva Diz, Bin Cao, Olga Lancho Medina, Eric Chiles, Amer Al-Asadi, Maya Aleksandrova, Shirley Luo, Amartya Singh, Hanlin Tao, Hossein Khiabanian, Xiaoyang Su, Victor Jin, **David Augeri**. A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia, Blood, **2021**, 138, 1317(April 22).

Alasadi, Amer, Bin Cao, Jingjing Guo, Hanlin Tao, Juan Collantes, Victor Tan, Xiaoyang Su, **David Augeri**, and Shengkan Jin. "Mitochondrial uncoupler MB1-47 is efficacious in treating hepatic metastasis of pancreatic cancer in murine tumor transplantation models." *Oncogene* 40, no. 12 **2021**: 2285-2295.

Gilleran, John A., Xin Yu, Alan J. Blayney, Anthony F. Bencivenga, Bing Na, **David J. Augeri**, Adam R. Blanden et al. "Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53." *Journal of Medicinal Chemistry* **2021**, 64, 2024-2045.

Nanjoo Suh, Hubert Maehr and **David Augeri** Vitamin D compounds and Cancer Stem Cells in Cancer Prevention as Book Chapter on pp.143 - 159 in Natural Products for Cancer Chemoprevention **2020**, DOI: 10.1007/978-3-030-39855-2_5.

JE Langenfeld, A Mondal, R NeMoyer, E Langenfeld, D Glover, M Scott, L Lairson, A Zloza, **D Augeri**, J Gilleran, Y Peng, J Roberge Bone morphogenetic protein (BMP) receptor inhibitor JL5 synergizes with Ym155 to induce AIF-caspase independent cell death. Research Square, **2020,** DOI: 10.21203/rs.3.rs-20532/v1

Rachel NeMoyer, Arindam Mondal, Mehul Vora, Elaine Langenfeld, Danea Glover, Michael Scott, Lauren Lairson, Christopher Rongo, **David J Augeri**, Youyi Peng, Salma K Jabbour, John Langenfeld Targeting bone morphogenetic protein receptor 2 sensitizes lung cancer cells to TRAIL by increasing cytosolic Smac/DIABLO and the downregulation of X-linked inhibitor of apoptosis protein *Cell Communication and Signaling* **2019**, *17*, (12), 1-13.

Newman, JH; NeMoyer, R. E**.; Augeri, D. J**.; Malhotra, J.; Langenfeld, J. Abstract LB-189: Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. Cancer Research, **2019**, 78, (13_Supplement), LB-189.

Newman, JH* **Augeri, DJ***, NeMoyer, R., Malhotra, J., Langenfeld, E. Chesson, CB, Dobias, NB, Lee, MB, Tarabichi, S., Jhawar, SR, Sadimin, ET, Kerrigan, JT, Goedken, M., Minerowicz, C., Jabbour, SK, Li, S., Zloza, A., Langenfeld, J. Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer *Oncogene,* **2018,** *37*, 3672.

Hussein, M., Bartucci, M., Patrizii, M., Flaherty, K., Huselid, E., Kui, C., Bigos, R., Gilleran, J. Kimball, D., **Augeri, D.**, Sabaawy, H. Synthesis and characterization of novel BMI-1 inhibitors targeting cellular self-renewal in hepatocellular carcinoma; Targeted Oncology, **2017**,1-14.

Augeri, D.J.; Langenfeld, E.; Castle, M.; Gilleran, J. A.; Langenfeld J. "Inhibiting The BMP and TGFβ Receptors Downregulates expression of XIAP and TAK1 leading to death of lung cancer cells." *Molecular Cancer*,**2016,** *15*, 27.

Yu, X., Blanden, A.R., Tsang, A.T., Zaman, S., Gilleran, J., **Augeri, D.J**., Kimball, S. D., Loh, S., Carpizo, D.R., Restoration of wildtype structure and function of mutant p53 by thiosemicarbazones using a novel zinc metallochaperone based mechanism, *Cancer Research*, **2016**, 3833.

Yu, X., Blanden, A.R., Tsang, A.T., Zaman, S., Gilleran, J., **Augeri, D.J**., Kimball, S. D., Carpizo, D.R., Translating a mutant p53 by thiosemicarbazones using a novel zinc metallochaperone-based mechanism *Cancer Research*, **2016**, 2097.

Blanden, A.R., Yu, X., Wolfe, A. J., Gilleran, J. A., **Augeri, D. J**., O'Dell, R. F., Olson, E.C., Kimball, S. D., Emge, T. J., Movileanu, L., Carpizo, D. R., Loh, S.N., Synthetic metallochaperone ZMC1 rescues mutant p53 by transporting Zn^{2+} into cells and buffering intracellular Zn^{2+} concentration"Molecular Pharmacology, **2015**, *87,* 825-831.

X. Yu, A. R. Blanden, S. Narayanan, L. Jayakumar, D. Lubin, **D. Augeri**, S. D. Kimball, S. N. Loh*, and D. R. Carpizo Small molecule restoration of wildtype structure--function of mutant p53 using a novel zinc- metallochaperone based mechanism, Oncotarget, **2014**, *5(19)*, 8879.

S. Konstantin V; B. Hamman; C. W. Chun; J. Kanchan G; A. Amin; J. Crisostomo; C. Wilkins; A. M. Digeorge-Foushee; J. Allen; N. Patel; S. Gopinathan; J. Zhou; A. Nouraldeen; T. Jessop; J. Bagdanoff; **D. J.** Augeri; R. Read ; P. Vogel; J. Swaffield ; A. Wilson ; K. Platt; K. G. Carson; A. Main ; B. Zambrowicz; T. Oravecz, Genetic Deletion of Mst1 Alters T Cell Function and Protects against Autoimmunity PLoS ONE, **2014**, *9(5)*, 98151.

Oravecz, T.; Chang, W. C.; Jhaver, K. G.; Al-Shami, A.; Jessop. T. C.; Hamman, B.; Bagdanoff, J. T.; **Augeri, D.** J.; Vogel, P.; Swaffield, J.; Wilson, A.; Carson, K. G.; Main, A.; Zambrowicz, B. P. Genetic and Pharmacologic Inhibition of MST1 Blocks Lymphocyte Function and Protects Against Inflammation and Autoimmunity, Ann Rheum Dis, **2013**, *72*, 118.

Oravecz, T.; **Augeri, D**. Anti-Inflammatory Drug Discovery, contributed chapter "Tipping the Balance of Sphingosine 1-Phosphate Production: Sphingosine Kinases and Sphingosine 1- Lyase as Immune Therapeutic Targets : Royal Chemistry Society, **2012**, Drug Discovery Series, 26, Anti Inflammatory Drug Discovery, 444-477.

Bagdanoff, J. T; Donoviel, M.S.; Nouraldeen, A.; Carlsen, M; Jessop, T. C.;Tarver, J.; Aleem, S; Dong, L.; Zhang, H.;Yan, J.; Bednarz, M.; Layek, S.; Hazelwood, J.; Owusu, I. B.; Gopinathan, S.; Moran, L.; Lai, Z.; Boteju, L.; Kramer, J.; Kimball, S.D.; Yalamanchili, P.; Heydorn, W.E.; Frazier, K.E.; Brooks, B.; Brown, P.; Wilson, A.; Sonnenburg, W. K.; Main, A.; Carson, K.G.; Oravecz, T.; **Augeri, D. J.*** Inhibition of Sphingosine 1-Phosphate Lyase for the Treatment of Rheumatoid Arthritis: Discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932) Journal of Medicinal Chemistry **2010**, 8650-8662.

Jessop, T.; Tarver, J. E.; Carlsen, M.; Xu, A.; Healy, J. P.; Heim-Riether, A. Fu, Q.; Taylor, J. A.; **Augeri, D. J**.; Shen, M.; Stouch, T. R.; Swanson, R. V.; Tari, L. W.; Hunter, M.; Hoffman, I.; Keyes, P. E.; Yu, XC; Miranda, M. Liu, Q.; Swaffield, J. C.; D. Kimball, S.; Nouraldeen, A.; Wilson, A. G. E.; DiGeorge Foushee, A.M.; Jhaver, K. Finch, R.; Anderson, S. Oravecz, T.; Carson, K.G. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters **2009**, *19(23),* 6784-6787

Tarver, J. E.; Jessop, T. C.; Carlsen, M.; **Augeri, D. J**.; Fu, Q.; Healy, J. P.; Heim-Riether, A.; Xu, A.; Taylor, J. A.; Shen, M.; Keyes, P. E.; D. Kimball, S.; Yu, X-C.; Miranda, M.; Liu, Q.; Swaffield, J. C.; Nouraldeen, A.; Wilson, A. G. E.; Finch, R. Jhaver, K.; DiGeorge Foushee, A.; Anderson, S.; Oravecz, T.; Carson, K. G. 5-Fluorocytosine derivatives as inhibitors of deoxycytidine kinase Bioorganic & Medicinal Chemistry Letters **2009**, *19(23),* 6780-6783

Bagdanoff, J. T.; Donoviel, M. S.; Nouraldeen, A. ; Tarver, J.; Fu, Q.; Carlsen, M.; Jessop, T.; Zhang, H.; Hazelwood, J.; Nguyen, H. ; Baugh, S. D. P.; Gardyan, M.; Terranova, K. M.; Barbosa, J.; Yan, J. ; Bednarz, M.; Layek, S.; Taylor, J.; Digeorge-Foushee, A.; Gopinathan, S.; Bruce, D.; Smith, T.; Moran, L.; O'Neill, E.; Kramer, J.; Lai, Z.; Kimball, S. D.; Liu, Q.; Sun, W.; Yu, S.; Swaffield, J.; Wilson, A.; Main, A.; Carson, K. G.; Oravecz, T.; **Augeri, D. J.** * Inhibition of sphingosine-1-phosphate lyase for the treatment of autoimmune disorders. Journal of Medicinal Chemistry **2009**, *52(13)*, 3941-3953

Jessop, T. C.; Tarver, J. E., Jr.; DiGeorge-Foushee, A.; Jhaver, K. G.; Taylor, J. A.; Xu, X.; Fu, Q.; Carlsen, M.; Shen, M.; Yu, X.; Liu, Ziye; M., Maricar L.; Nouraldeen, A.; Yu, X.; Tari, L. W.; Hunter, M. J.; Hoffman, I. D.; Wilson, A. G. E.; Anderson, S. J.; Oravecz, T.; Stouch, T. R.;

Augeri, D. J.; Carson, K. G. Lead optimization and structure-based design of deoxycytidine kinase inhibitors with potent in vitro and in vivo activity**.** 236th ACS National Meeting, **2008,** Philadelphia, PA

Oravecz,T., Donoviel, M.S., Anderson, S. Carson, K., Sun, W., Swaffield,J., Liu, Q., Kimball, S.D., Piggott, J.A., Main, Zambrowicz, B., Sands, A., Turner, A. **Augeri, D. J.** Genetic and Chemical Inhibition of Sphingosine 1-Phosphate Lyase Results in Peripheral Lymphopenia and Alleviates Disease Development in Animal Models of Inflammation and Autoimmunity *Blood* **2007** *110,* 2292.

Simpkins, L. M.; Bolton, S.; Pi, Z.; Sutton, J. C.; Kwon, C.; Zhao, G.; Magnin, D. R.; **Augeri, David J**.; Gungor, T.; Rotella, D. P.; Sun, Z.; Liu, Yajun; S.;William S.; Marcinkeviciene, J.; Robertson, J. G.; Wang, A.; Robl, J. A.; Atwal, K. S.; Zahler, R. L.; Parker, R. A.; Kirby, M. S.; Hamann, L. G. Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors Bioorganic & Medicinal Chemistry Letters **2007**, *17(23)*, 6476-6480.

Hamann, Lawrence G.; Manfredi, Mark C.; Sun, Chongqing; Krystek, Stanley R.; Huang, Yanting; Bi, Yingzhi; **Augeri, David J**.; Wang, Tammy; Zou, Yan; Betebenner, David A.; Fura, Aberra; Seethala, Ramakrishna; Golla, Rajasree; Kuhns, Joyce E.; Lupisella, John A.; Darienzo, Celia J.; Custer, Laura L.; Price, Jennifer L.; Johnson, James M.; Biller, Scott A.; Zahler, Robert; Ostrowski, Jacek. Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators *Bioorganic & Medicinal Chemistry Letters* **2007**, *17(7)*, 1860-1864.

Petros, Andrew M.; Dinges, Jurgen; **Augeri, David J**.; Baumeister, Steven A.; Betebenner, David A.; Bures, Mark G.; Elmore, Steven W.; Hajduk, Philip J.; Joseph, Mary K.; Landis, Shelley K.; Nettesheim, David G.; Rosenberg, Saul H.; Wang, Shen; Thomas, Sheela; Wang, Xilu; Zanze, Irini; Zhang, Haichao; Fesik, Stephen W. Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-xL from NMR and Parallel Synthesis *J. Med. Chem,* **2006***, 49(2),* 656-663

Augeri, David J.*; Robl, Jeffrey A.; Betebenner, David A. ; Magnin, David R.; Khanna, Ashish; Robertson, James G.; Wang, Aiying; Simpkins, Ligaya M.; Taunk, Prakash; Huang, Qi; Han, Song-Ping ; Abboa-Offei, Benoni; Cap, Michael; Xin, Li; Tao, Li ; Tozzo, Effie; Welzel, Gustav E.; Egan, Donald M.; Marcinkeviciene, Jovita; Kirby, Mark S.; Biller, Scott; Parker, Rex A.; Hamann, Lawrence G.* Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes *J. Med. Chem.* **2005**, *48*, 5025-5037

Oltersdorf, Tilman; Elmore, Steven W.; Shoemaker, Alexander R.; Armstrong, Robert C.; **Augeri, David J**.; Belli, Barbara A.; Bruncko, Milan; Deckwerth, Thomas L.; Dinges, Jurgen; Hajduk, Philip J.; Joseph, Mary K.; Kitada, Shinichi; Korsmeyer, Stanley J.; Kunzer, Aaron R.; Letai, Anthony; Li, Chi; Mitten, Michael J.; Nettesheim, David G.; Ng, Shi Chung; Nimmer, Paul M.; O'Connor, Jacqueline M.; Oleksijew, Anatol; Petros, Andrew M.; Reed, John C.; Shen, Wang; Tahir, Stephen K.; Thompson, Craig B.; Tomaselli, Kevin J.; Wang, Baole; Wendt, Michael D.; Zhang, Haichao; Fesik, Stephen W.; Rosenberg, Saul H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours**.** *Nature*, **2005**, 435 (7042), 677-681

Magnin, David R.; Robl, Jeffrey A; Sulsky, Richard B.; **Augeri, David J**.; Huang Yanting, Simpkins, Ligaya M.; Taunk , Prakash C., Betebenner , David A., Robertson, James G.;Benoni E. Abboa-Offei;Wang, Aiying; Cap, Michael; Xin, Li;Tao;Li; Sitkoff, Doree F.Malley,O Gougoutas,O Jack Z.;Khanna, Ashish , Huang Qi ; Han Sng-Ping; Parker;Rex; Hamann Lawrence G. Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of r-Aminoacyl-L-*cis*-4,5-methanoprolinenitrile-Based Inhibitors *J. Med. Chem.* **2004**, *47*, 2587-2598.

Hajduk, Philip J.; Shuker, Suzanne B.; Nettesheim, David G.; Craig, Richard; **Augeri, David J**.; Betebenner, David; Albert, Daniel H.; Guo, Yan; Meadows, Robert P.; Xu, Lianhong; Michaelides, Michael; Davidsen, Steven K.; Fesik, Stephen W. NMR-Based Modification of Matrix Metalloproteinase Inhibitors with Improved Bioavailability *J. Med. Chem.* **2002**, *45*, 5628-5639.

Hajduk, Philip J.; **Augeri, David J**.; Mack, Jamey; Mendoza, Renaldo; Yang, Jianguo; Betz, Stephen F.; Fesik, Stephen W. NMR-Based Screening of Proteins Containing 13C-Labeled Methyl Groups. *J. Am. Chem. Soc.* **2000**, *122*,7898-7904.

Hajduk, Philip J.; Dinges, Juergen; Schkeryantz, Jeffrey M.; Janowick, David; Kaminski, Michele; Tufano, Michael; **Augeri, David J**.; Petros, Andrew; Nienaber, Vicki; Zhong, Ping; Hammond, Rachel; Coen, Michael; Beutel, Bruce; Katz, Leonard; Fesik, Stephen W. Novel Inhibitors of Erm Methyltransferases from NMR and Parallel Synthesis, *J. Med. Chem.*, **1999**, *42*, 3852-3859.

Augeri, David J*.; Janowick, Dave; Kalvin, Douglas; Sullivan, Gerry; Larsen, John; Dickman, Daniel; Ding, Hong; Cohen, Jerry; Lee, Jang; Warner, Robert; Kovar, Peter; Cherian, Sajeev; Saeed, Badr; Zhang, Haichao; Tahir, Steve; Ng, Shi-Chung; Sham, Hing; Rosenberg, Saul H. Potent and Orally Bioavailable Noncysteine-containing Inhibitors of Protein Farnesyltransferase. *Bioorg. Med. Chem. Lett.*, **1999**, *9*, 1069-1074.

Augeri, David J*.; O'Connor, Stephen J.; Janowick, Dave; Szczepankiewicz, Bruce; Sullivan, Gerry; Larsen, John; Kalvin, Douglas; Cohen, Jerry; Devine, Edward; Zhang, Haichao; Cherian, Sajeev; Saeed, Badr; Ng, Shi-Chung; Rosenberg, Saul. Potent and Selective Non-Cysteine-Containing Inhibitors of Protein Farnesyltransferase *J. Med. Chem.* **1998**, *41*, 4288-4300.

Augeri, David J.; Chamberlin, A. Richard. N-Aminoaziridinylhydrazones: Highly Diastereoselective Alkylation Without Chelation, and a Syn-Directing Effect *Tetrahedron Lett.* **1994**, *35*, 5599-602.

Kim, Soong-Hoon; **Augeri, David**; Yang, Dan; Kahne, Daniel Concise Synthesis of the Calicheamicin Oligosaccharide Using the Sulfoxide Glycosylation Method *J. Am. Chem. Soc.* **1994**, *116*, 1766-75.

Newhouse, Bradley J.; Bordner, Jon; **Augeri, David J**.; Litts, Christopher S.; Kleinman, Edward F. Novel [3+2] and [3+3] 4-Quinolone Annulations by a Tandem Claisen-Cope Amidoalkylation Reaction, *J. Org. Chem.* **1992**, *57*, 6991-5.

Augeri, David J.; Fray, Andrew H.; Kleinman, Edward F. Synthesis and Antibacterial Activity of 2,3-Dehydroofloxacin, *J. Heterocycl. Chem.* **1990**, *27*, 1509.

Fray, Andrew H.; **Augeri, David J**.; Kleinman, Edward F. A Convenient Synthesis of 3,6-Disubstituted 3,6-Diazabicyclo[3.2.2]nonanes and 3,6-Diazabicyclo [3.2.1]octanes, *J. Org. Chem.* **1988**, *53*, 896-9.

Issued U.S. Patents (63) – 53 patents listed here (https://scholar.google.com/citations?user=HlVtCuAAAAAJ&hl=en)

David J Augeri, Anthony F Bencivenga, Adam Blanden, Darren R Carpizo, John A Gilleran, Spencer David Kimball, Stewart N Loh, Xin Yu, Hydrazone derivatives for the treatment of cancer United States Patent **10,828,288**

David J Augeri, Anthony F Bencivenga, Adam Blanden, Darren R Carpizo, John A Gilleran, Spencer David Kimball, Stewart N Loh, Xin Yu, Zinc complexes of hydrazones and (thio) semicarbazones and their use for the treatment of cancer United States Patent **10,729,671**

David J Augeri, Anthony F Bencivenga, Adam Blanden, Darren R Carpizo, John A Gilleran, Spencer David Kimball, Stewart N Loh, Xin Yu, (Thio, oxo, and seleno) semicarbazone derivatives and their use for treating cancer United States Patent **10,604,480**

Augeri, D. J., Sabaawy, H.E. Therapeutic Compounds, United States Patent **10,875, 861**

David J Augeri, Anthony F Bencivenga, Adam Blanden, Darren R Carpizo, John A Gilleran, Spencer David Kimball, Stewart N Loh, Xin Yu, United States Patent **10,604,481**

Jin, S., **Augeri, D.J.,** Kimball, S.D., Liu, P., Hanlin, T., Xiangang, Z. Mitochondrial Uncouplers for the treatment of metabolic diseases and cancer United States Patent **10,525,021**

Augeri, D.J., Bagdanoff, J.T., Baugh, S. D.. P., Carlsen, M., Carson, K.G., Gilleran, J.A., He, W., Oravecz, T., Salojin, K., Sung, L. MST1 kinase inhibitors and methods of their use, United States Patent **8, 440, 652**.

Augeri, D.J., Bagdanoff, J., Baugh, S.D.P., Carson, K.G., Jessop, T. , Kimball, S. D. Methods of Treating Ulcerative Colitis, United States Patent, **8,404,732**.

Augeri, D.J., Tarver, J.E., Fu, Q., Voronkov, Hackley, D., Mertzman, M.E., Carlsen, M. Aryl pyridines and methods od their use United States Patent **8,153,804**.

Augeri, D.J., Bagdanoff, J., Boteju, L. W., Carson, K.G., Jessop, T. , Kimball, S. D. Methods of Treating Rheumatoid Arthritis, United States Patent, **8,093,267**.

Augeri, D.J., Carlsen, M, Carson, K.G., Fu, Q., Heim-Riether, A., Jessop, T. C., Tarver, J.E., Taylor, J. A. 4-amino-1H-pyrimidin-2-one compounds, compositions comprising them and methods of their use, United States Patent, **8,093, 245.**

Wendt, M.D., Ding, H., Thomas. S.A., Elmore, S. W., Shen, W., Dickman, D. A., **Augeri. D.J**. Biaryl carboxylic acid apoptosis promoters United States Patent **7, 989, 656**

DJ Augeri, J Bagdanoff, SDP Baugh, KG Carson, TC Jessop, JE Tarver Heterocyclic compounds, compositions comprising them and

methods of their use United States Patent, **7,825, 142**.

Sun, C., Hamann, L., **Augeri, D**., Bi, Y., Robl, J., Huang, Y.T., Wang, T., Holubec, A., Simpkins, L., Sutton, J. C., Li, J. Bicyclic Modulators of androgen receptor function, United States Patent **7,772,267**

Augeri, David J.; Bagdanoff, Jeffrey; Boteju, Lakmal W.; Carson, Kenneth G.; Jessop, Theodore C.; Kimball, Spencer David. Imidazole-based compounds, compositions comprising them and methods of their use, Unitesd States Patent, **7,649, 098**

Augeri, David J.; Bagdanoff, Jeffrey; Baugh, Simon D. P.; Carson, Kenneth G.; Jessop, Theodore C.; Tarver, James E. Preparation of azolylimidazolylbutanetetraols as sphingosine-1-phosphate (S1P) modulators for treatment of autoimmune and inflammatory disorders United States Patent **7,598,280**

Augeri, David J.; Steven A. Baumeister, Milan Brunko, Daniel A. Dickman, Hong Ding, Jurgen Dinges, Stephen W. Fesik, Philip J. Hajduk, Aaron R. Kunzer, David G. Nettesheim, Thorsten Oost, Andrew Petros, Saul H. Rosenberg, Wang Shen, Sheela A. Thomas, Xilu Wang, Michael D. Wendt. N-acylsulfonamide Apoptosis Promoters, 2009, United States Patent **7,504,512**

Vu, Truc Chi; Brzozowski, David B.; Fox, Rita; Godfrey, Jollie Duaine, Jr.; Hanson, Ronald L.; Kolotuchin, Sergei V.; Mazzullo, John A., Jr.; Patel, Ramesh N.; Wang, Jianji; Wong, Kwok; Yu, Jurong; Zhu, Jason; Magnin, David R.; **Augeri, David J.**; Hamann, Lawrence G. Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates United States Patent **7,420,079**

Augeri, David J.; Baumeister, Steven A.; Bruncko, Milan; Dickman, Daniel A.; Ding, Hong; Dinges, Jurgen; Fesik, Stephen W.; Hajduk, Philip J.; Kunzer, Aaron R.; McClellan, William; Nettesheim, David G.; Oost, Thorsten; Petros, Andrew M.; Rosenberg, Saul H.; Wang, Shen; Thomas, Sheela A.; Wang, Xilu; Wendt, Michael D. N- Preparation of N-Arylcarbonyl- and Heteroarylcarbonyl Benzenesulfonamide Inhibitors of Bcl-Xl and Bcl-2 as Promoters of Apoptosis United States Patent, **6,720,338**

David J. Augeri, Steven A. Baumeister, Daniel A. Dickman, Hong Ding, Jurgen Dinges, Stephen W. Fesik , Philip J. Hajduk, William McClellan, David G. Nettesheim, Thorsten Oost, Andrew M. Petros, Saul H. Rosenberg, Wang Shen, Sheela A. Thomas, Xilu Wang, Michael D. Wendt **N-acylsulfonamide apoptosis promoters;** United States Patent **6,720,338**

Sun, C., Robl, JA, Salvati, ME, Wang, T., Hamann, L., **Augeri, D.** Bicyclic Modulators of Androgen Receptor Function, United States Patent **6,670, 386**.

Truc Chi Vu, David B Brzozowski, Rita Fox, Jollie Duaine Godfrey Jr, Ronald L Hanson, Sergei V Kolotuchin, John A Mazzullo, Ramesh N Patel, Jianji Wang, Kwok Wong, Jurong Yu, Jason J Zhu, David R Magnin, **David J Augeri,** Lawrence G Hamann Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof United States Patent **7,420,079**

Truc Chi Vu, David B Brzozowski, Rita Fox, Jollie Duaine Godfrey Jr, Ronald L Hanson, Sergei V Kolotuchin, John A Mazzullo, Ramesh N Patel, Jianji Wang, Kwok Wong, Jurong Yu, Jason J Zhu, David R Magnin, David J Augeri, Lawrence G Hamann Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof United States Patent **7,705,033**

Robl, Jeffrey A.; Sulsky, Richard B.; **Augeri, David J.**; Magnin, David R.; Hamann, Lawrence G. **Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV** United States Patent **6,395,767**

Sebti, Said M.; Hamilton, Andrew D.; **Augeri, David J**.; Barr, Kenneth J.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorenson, Bryan K.; Sullivan, Gerard M.; Tasker, Andrew S.; Wasicak, James T.; Nelson, Lissa T. J.; Henry, Kenneth J.; Wang, Le. Inhibitors of protein isoprenyl transferases United States Patent, **6,310,095**

Augeri, David J.; Betebenner, David A.; Craig, Richard; Davidsen, Steven K.; Fesik, Stephen W.; Giesler-Stacey, Jamie R.; Guo, Yan; Hajduk, Philip J.; Michaelides, Michael R.; Nettesheim, David G Inhibitors of Matrix Metalloproteinase Inhibitors, United States Patent **6,288,261**

Sebti, Said M.; Hamilton, Andrew D.; **Augeri, David J**.; Barr, Kenneth J.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorensen, Bryan K.; Sullivan, Gerard M.; Tasker, Andrew S.; Wasicak, James T.; Nelson, Lissa T. J.; Henry, Kenneth J.; Wang, Le; Liu, Gang; Gunawardana, Indrani W. Inhibitors of protein isoprenyl transferases. United States Patent **6,204,293**

Sebti, Said M.; Hamilton, Andrew D.; **Augeri, David J**.; Barr, Kenneth J.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorensen, Bryan K.; Sullivan, Gerard M.; Tasker, Andrew S.;

Wasicak, James T.; Nelson, Lissa T. J.; Henry, Kenneth J.; Wang, Le; Inhibitors of protein isoprenyl transferases. United States Patent, **6,310,095**

Arendsen , D. L.; **Augeri, D. J.;** Baker, W. R.; Fakhhoury, S. A.; Fung, A. R.; Garvey, D. S.; McClellan, W. J.; O'Connor, S. J.; Prasad, R. N.; Rockway, T. W.; Rosenberg, S. H.; Stein, H.; Shen, W.; Stout, D. M.; Sullivan, G. M. Inhibitors of Squalene Synthase and Protein Farnesyltransferase. United States Patent, **5, 831,115**

Fesik, Stephen W.; **Augeri, David J.** Site-Specific 13C/14C-Labeled Proteins, Amino Acids, and Biochemical Precursors United States Patent **6,897,337**

Sebti, Said M.; Hamilton, Andrew D.; **Augeri, David J**.; Barr, Kenneth J.; Donner, Bernard G.; Fakhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; Larsen, John J.; Liu, Gang; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Swenson, Rolf E.; Sorensen, Bryan K.; Sullivan, Gerard M.; Szczepankiewicz, Bruce G.; et al. Inhibitors of Protein Isoprenyl Transferases, United States Patent **6,693,123**

Sebti, Said M.; Hamilton, Andrew D.; Rosenberg, Saul H.; **Augeri, David J**.; Barr, Kenneth J.; Donner, Bernard G.; Janowick, David A.; Kalvin, Douglas M.; Larsen, John J.; Liu, Gang; O'Connor, Stephen J.; Shen, Wang; Swenson, Rolf E.; Sorenson, Bryan K.; Sullivan, Gerard M.; Szczepankiewicz, Bruce; Tasker, Andrew S.; Wasicak, James T.; Winn, Martin. Inhibitors of Protein Isoprenyl Transferases 1997, United States Patent **6,694,104**

Bhanot, Purnima; **Augeri, D.J.**; Gilleran, J. A.; Fondekar, R. Therapeutic Methods and Compounds, U.S. Patent enters Non-Provisional Status, 2022, U.S. Patent App. 17/605,732 (antimalaria compounds-Kinase inhibitors).

Augeri, David J.; Sabaawy, H.; Gilleran, John A. Therapeutic Compounds and Methods of Their Use, 2022, U.S. Patent Appl. 17/297,397.

Augeri, David J.; Bencivenga, Anthony F.; Blanden, Adam; Carpizo, Darren R.; Gilleran, John A.; Kimball, Spencer David; Loh, Stewart N.; Yu, Xin Preparation of SemiCarbazone Complexes with Zinc for treating cancer WO2016123256

Augeri, David J.; Bencivenga, Anthony F.; Blanden, Adam; Carpizo, Darren R.; Gilleran, John A.; Kimball, Spencer David; Loh, Stewart N.; Yu, Xin Hydrazone derivatives for the treatment of cancer and their preparation. WO2016123253

Augeri, David J.; Bencivenga, Anthony F.; Blanden, Adam; Carpizo, Darren R.; Gilleran, John A.; Kimball, Spencer David; Loh, Stewart N.; Yu, Xin Preparation of Zinc Complexes of hydrazones and (thio)semicarbazones for the treatment of cancer From PCT Int. Appl. (2016), WO 2016123250 A1 20160804. And three other applications related to this app. One large patent split into 4 separate applications.

Carpizo, Darren, R.; **Augeri, David, J**.; Gilleran, John, A.; Kimball, S. David; Yu, Xin; Loh, Stewart, N. Pharmaceutical Compounds and Methods. U.S. Provisional 62/108,415 (filed Jan 2015)

Jin, Shengkan; **Augeri, David**, J.; Kimball, S. David; Liu, Peng; Tao, Hanlin. Mito Novel Modulators of Mitochondrial Function for Treatment of Obesity and Type II Diabetes U.S. Provisional 62/081,412 (filed Nov 2014)

Augeri, DJ, Bagdanoff, JT, Baugh, SDP; Carlsen, M, Carson, KG, Gilleran, JA, He, W; Oravecz, T, Salojin, K, Sung, L Preparation of benzenesulfonamides as Mst-1 inhibitors U.S. Pat. Appl. Publ. (2012), US 20120225857

Augeri, David J.; Carlsen, Marianne; Carson, Kenneth G.; Fu, Qinghong; Heim-Riether, Alexander; Jessop, Theodore C.; Tarver, James; Taylor, Jerry A. Preparation of 4-amino-1H-pyrimidin-2-one based compounds as deoxycytidine kinase inhibitors**.** PCT Int. Appl. (2008), WO 2008076778 66pp.

Augeri, David; Tarver, James; Fu, Qinghong; Voronkov, Michael Victor; Hackley, Doan; Mertzman, Michael E.; Carlsen, Marianne. Preparation of aryl pyridines via palladium-catalyzed coupling reaction PCT Int. Appl. (**2007**). WO/2007016674

Wendt, Michael D.; Shen, Wang; Dickman, Daniel A.; Ding, Hong; Thomas, Sheela A.; **Augeri, David**; Elmore, Steven W. Preparation of biphenyl carboxylic acid derivatives as apoptosis promoters**,** PCT Int. Appl. (**2007**),WO/2007008627.

Li, James J.; Hamann, Lawrence; **Augeri, David**; Bi, Yingzhi. Preparation of pyrrolizines as modulators of androgen receptor function, U.S. Pat. Appl. Publ. (**2005**),24 pp. US 2005197367

Li, James J.; Hamann, Lawrence; **Augeri, David**; Bi, Yingzhi. Novel bicyclic compounds as modulators of androgen receptor function and method, U.S. Pat. Appl. Publ. US 20050197367.

Sun, Chongqing; Hamann, Lawrence; **Augeri, David**; Bi, Yingzhi; Robl, Jeffrey; Huang, Yan-ting; Wang, Tammy; Simpkins, Ligaya; Holubec, Alexandra. Preparation of Pyrrolo[1,2-c]imidazoles as Bicyclic Modulators of Androgen Receptor Function. PCT Int. Appl. (2003),177 pp. WO 2003096980

Sun, Chongqing; Robl, Jeffrey A.; Salvati, Mark E.; Wang, Tammy; Hamann, Lawrence; **Augeri, David**. Preparation of Imidazole-containing Heterobicyclic Modulators of Androgen Receptor Function PCT Int. Appl. (2003), WO 2003011824

Sebti, Said M.; Hamilton, Andrew D.; **Augeri, David J**.; Barr, Kenneth J.; Donner, Greg B.; Fakhoury, Stephen A.; O'Connor, Stephen J.; Rosenberg, Saul H.; Shen, Wang; Szczepankiewicz, Bruce G.; Gunawardana, Indrani W. Preparation of Amino Acid Derivatives as Inhibitors of Protein Isoprenyl Transferases, U.S. Pat. Appl. Publ. (2002), 499 pp US 2002193596 A1 2002 CAN 138:39539 AN 2002:965163

McClellan, William; Oost, Thorsten; Bruncko, Milan; Wang, Xilu; **Augeri, David J.**; Baumeister, Steven A.; Dickman, Daniel A.; Ding, Hong; Dinges, Jurgen; Fesik, Stephen W.; Hajduk, Philip J.; Kunzer, Aaron R.; Nettesheim, David G.; Petros, Andrew M.; Rosenberg, Saul H.; Shen, Wang; Thomas, Sheela A.; Wendt, Michael D. N- Preparation of N-Arylcarbonyl- and Heteroarylcarbonyl Benzenesulfonamide Inhibitors of Bcl-Xl and Bcl-2 as Promoters of Apoptosis PCT Int. Appl. (2002), 292 pp. WO 0224636